珠江三角洲地区泌尿系结石组分与尿微晶性质研究  

Study on composition of urinary stones and the property of urinary crystallites in Pearl River Delta area

作　　者：黄志杰[1] 姚秀琼[1] 欧阳健明[1] 梁蔚波[2] 

机构地区：[1]暨南大学生物矿化与结石病防治研究所,广州510632 [2]暨南大学附属第一医院泌尿外科,广州510630

出　　处：《广东医学》2010年第1期66-68,共3页Guangdong Medical Journal

基　　金：国家自然科学基金项目(编号:30672103);广东省科技攻关项目(编号:2005B30701003);广州市重点科技项目(编号:2001-Z-123-01)

摘　　要：目的分析近年来珠江三角洲地区泌尿系结石患者的结石组分和尿微晶性质,期望为尿石症的预防和治疗提供启示。方法采用X射线衍射(XRD)和傅立叶变换红外光谱(FT-IR)对随机抽样的30例结石样本进行联合分析;同时采用纳米粒度仪研究尿石症患者尿液中纳米微晶的平均粒径、粒度分布、多分散系数(PDI)和Zeta电位等性质,并与健康对照者进行比较。结果珠江三角洲地区泌尿系结石以草酸钙结石为主,占76.6%;其次为尿酸结石,占16.7%;磷酸钙结石约占6.7%。尿石症患者尿微晶的平均粒径、粒度分布、多分散系数(PDI)和Zeta电位与健康对照者比较差异有统计学意义。结论草酸钙、尿酸和磷酸钙构成了珠江三角洲地区泌尿系结石的主要成分;尿石症患者和健康对照者尿微晶在平均粒径、粒度分布、多分散系数(PDI)和Zeta电位等方面性质的差异使得正常人不容易得结石。Objective To seek the methods in the prevention and treatment of urinary stones, stone composition and the property of urinary crystallites of lithogenic patients in Pearl River Delta area in recent years were analyzed. Meth- ods Thirty random stone samples were investigated by XRD and NY - IR method. The mean diameter, particle size dis- tribntion, polydispersity index（PDI） and Zeta potential of urinary nanocrystallites in lithogenic urines were investigated in nanoparticle size analyzer and were compared with those in healthy subjects. Results Calcium oxalate stone was the main urinary stones in Pearl River Delta area, which accounting for 76. 6%, and followed by uric acid and calcium phos- phate stones, which accounting for 16. 7% and 6. 7%, respectively. In urinary nanocrystallites, there was significant difference between lithogenic subjects and healthy subjects in mean diameter, particle size distribution, polydispersity in- dex （PDI） and Zeta potential. Conclusion Calcium oxalate, uric acid, and calcium phosphate were the main constitu- ents of urinary stones in Pearl River Delta area. The right mean diameter, particle size distribution, PDI and Zeta potential of urinary nanocrystallites prevent healthy subjects from lithangiuria.

关 键 词：泌尿系结石 纳米微晶 ZETA电位 

分 类 号：R277.514[医药卫生—中医学] R783.1